Literature DB >> 24667409

Quantitative evaluation of the cell penetrating properties of an iodinated Tyr-L-maurocalcine analog.

Céline Tisseyre1, Mitra Ahmadi2, Sandrine Bacot2, Lucie Dardevet1, Pascale Perret2, Michel Ronjat1, Daniel Fagret2, Yves Usson3, Catherine Ghezzi2, Michel De Waard4.   

Abstract

L-Maurocalcine (L-MCa) is the first reported animal cell-penetrating toxin. Characterizing its cell penetration properties is crucial considering its potential as a vector for the intracellular delivery of drugs. Radiolabeling is a sensitive and quantitative method to follow the cell accumulation of a molecule of interest. An L-MCa analog containing an additional N-terminal tyrosine residue (Tyr-L-MCa) was synthesized, shown to fold and oxidize properly, and successfully radioiodinated to (125)I-Tyr-L-MCa. Using various microscopy techniques, the average volume of the rat line F98 glioma cells was evaluated at 8.9 to 18.9×10(-7)μl. (125)I-Tyr-L-MCa accumulates within cells with a dose-dependency similar to the one previously published using 5,6-carboxyfluorescein-L-MCa. According to subcellular fractionation of F98 cells, plasma membranes keep less than 3% of the peptide, regardless of the extracellular concentration, while the nucleus accumulates over 75% and the cytosol around 20% of the radioactive material. Taking into account both nuclear and cytosolic fractions, cells accumulate intracellular concentrations of the peptide that are equal to the extracellular concentrations. Estimation of (125)I-Tyr-L-MCa cell entry kinetics indicate a first rapid phase with a 5min time constant for the plasma membrane followed by slower processes for the cytoplasm and the nucleus. Once inside cells, the labeled material no longer escapes from the intracellular environment since 90% of the radioactivity remains 24h after washout. Dead cells were found to have a lower uptake than live ones. The quantitative information gained herein will be useful for better framing the use of L-MCa in biotechnological applications. This article is part of a Special Issue entitled: Calcium Signaling in Health and Disease. Guest Editors: Geert Bultynck, Jacques Haiech, Claus W. Heizmann, Joachim Krebs, and Marc Moreau.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cell penetrating peptide; Drug delivery; Maurocalcine; Quantitative evaluation; Radioiodination

Mesh:

Substances:

Year:  2014        PMID: 24667409     DOI: 10.1016/j.bbamcr.2014.03.017

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  4 in total

1.  In cellulo phosphorylation induces pharmacological reprogramming of maurocalcin, a cell-penetrating venom peptide.

Authors:  Michel Ronjat; Wei Feng; Lucie Dardevet; Yao Dong; Sawsan Al Khoury; Franck C Chatelain; Virginie Vialla; Samir Chahboun; Florian Lesage; Hervé Darbon; Isaac N Pessah; Michel De Waard
Journal:  Proc Natl Acad Sci U S A       Date:  2016-04-11       Impact factor: 11.205

Review 2.  Scorpion venom components as potential candidates for drug development.

Authors:  Ernesto Ortiz; Georgina B Gurrola; Elisabeth Ferroni Schwartz; Lourival D Possani
Journal:  Toxicon       Date:  2014-11-26       Impact factor: 3.033

3.  Biodistribution, Stability, and Blood Distribution of the Cell Penetrating Peptide Maurocalcine in Mice.

Authors:  Pascale Perret; Mitra Ahmadi; Laurent Riou; Sandrine Bacot; Julien Pecher; Cathy Poillot; Alexis Broisat; Catherine Ghezzi; Michel De Waard
Journal:  Int J Mol Sci       Date:  2015-11-19       Impact factor: 5.923

4.  CPP-Ts: a new intracellular calcium channel modulator and a promising tool for drug delivery in cancer cells.

Authors:  Bárbara Bruna Ribeiro de Oliveira-Mendes; Carolina Campolina Rebello Horta; Anderson Oliveira do Carmo; Gabriela Lago Biscoto; Douglas Ferreira Sales-Medina; Hortênsia Gomes Leal; Pedro Ferreira Pinto Brandão-Dias; Sued Eustáquio Mendes Miranda; Carla Jeane Aguiar; Valbert Nascimento Cardoso; André Luis Branco de Barros; Carlos Chávez-Olortégui; M Fátima Leite; Evanguedes Kalapothakis
Journal:  Sci Rep       Date:  2018-10-03       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.